XOSPATA (gilteritinib)

SELF ADMINISTRATION

Indication for Prior Authorization:

  • Indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test

Patients must meet the following criteria for the indications above:

  • Patient is 18 years of age or older, AND

  • Diagnosis of relapsed or refractory AML confirmed by chart note documentation, AND

  • The patient has an FLT3 mutation as confirmed by an FDA approved test, AND

  • Prescribed by or in consultation with an oncologist

Dosing:

  • Oral: 120 mg once daily for a minimum of 6 months (to allow time for a clinical response) or until disease progression or unacceptable toxicity

  • Avoid concomitant use with P-gp and strong CYP3A inducers and CYP3A inhibitors

Approval:

  • Initial: 6 months

  • Renewal: 1 year

 

Last review date: April 16, 2019

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone